Metabolomics and Metabolic Reprogramming in Kidney Cancer

被引:76
|
作者
Weiss, Robert H. [1 ,2 ]
机构
[1] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA
[2] VA Northern Calif Hlth Care Syst, Med Serv, Sacramento, CA USA
基金
美国国家卫生研究院;
关键词
Kidney cancer; metabolomics; therapeutics; reprogramming; RENAL-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; TUMOR-SUPPRESSOR LKB1; P53-INDUCIBLE REGULATOR; REDUCTIVE CARBOXYLATION; GLUTAMINE-METABOLISM; ARGININE DEPRIVATION; GROWTH; INHIBITOR; AKT;
D O I
10.1016/j.semnephrol.2018.01.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney cancer, or renal cell carcinoma (RCC), is a disease of increasing incidence that commonly is seen in the general practice of nephrology. Despite this state of affairs, this fascinating and highly morbid disease frequently is under-represented, or even absent, from the curriculum of nephrologists in training and generally is underemphasized in national nephrology meetings, both scientific as well as clinical. Although classic concepts in cancer research in general had led to the concept that cancer is a disease resulting from mutations in the control of growth-regulating pathways, reinforced by the discovery of oncogenes, more contemporary research, particularly in kidney cancer, has uncovered changes in metabolic pathways mediated by those same genes that control tumor energetics and biosynthesis. This adaptation of classic biochemical pathways to the tumors advantage has been labeled metabolic reprogramming. For example, in the case of kidney cancer there exists a near-universal presence of von Hippel-Lindau tumor suppressor (pVHL) inactivation in the most common form, clear cell RCC (ccRCC), leading to activation of hypoxia-relevant and other metabolic pathways. Studies of this and other pathways in clear cell RCC (ccRCC) have been particularly revealing, leading to the concept that ccRCC can itself be considered a metabolic disease. For this reason, the relatively new method of metabolomics has become a useful technique in the study of ccRCC to tease out those pathways that have been reprogrammed by the tumor to its maximum survival advantage. Furthermore, identification of the nodes of such pathways can lead to novel areas for drug intervention in a disease for which such targets are seriously lacking. Further research and dissemination of these concepts, likely using omics techniques, will lead to clinical trials of therapeutics specifically targeted to tumor metabolism, rather than those generally toxic to all proliferating cells. Such novel agents are highly likely to be more effective than existing drugs and to have far fewer adverse effects. This review provides a general overview of the technique of metabolomics and then discusses how it and other omics techniques have been used to further our understanding of the basic biology of kidney cancer as well as to identify new therapeutic approaches. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [41] Lipid metabolic reprogramming in cancer cells
    Beloribi-Djefaflia, S.
    Vasseur, S.
    Guillaumond, F.
    ONCOGENESIS, 2016, 5 : e189 - e189
  • [42] Reprogramming the cancer epigenome by "metabolic transduction"
    Byun, Jung S.
    Gardner, Kevin
    FASEB JOURNAL, 2012, 26
  • [43] The cancer metabolic reprogramming and immune response
    Xia, Longzheng
    Oyang, Linda
    Lin, Jinguan
    Tan, Shiming
    Han, Yaqian
    Wu, Nayiyuan
    Yi, Pin
    Tang, Lu
    Pan, Qing
    Rao, Shan
    Liang, Jiaxin
    Tang, Yanyan
    Su, Min
    Luo, Xia
    Yang, Yiqing
    Shi, Yingrui
    Wang, Hui
    Zhou, Yujuan
    Liao, Qianjin
    MOLECULAR CANCER, 2021, 20 (01)
  • [44] Metabolic reprogramming and cancer progression in patients
    DeBerardinis, Ralph J.
    CANCER RESEARCH, 2024, 84 (05)
  • [45] Intracellular Transport in Cancer Metabolic Reprogramming
    Sneeggen, Marte
    Guadagno, Noemi Antonella
    Progida, Cinzia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [46] Metabolic reprogramming in epithelial ovarian cancer
    Nantasupha, Chalaithorn
    Thonusin, Chanisa
    Charoenkwan, Kittipat
    Chattipakorn, Siriporn
    Chattipakorn, Nipon
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (09): : 9950 - 9973
  • [47] Oxygen availability and metabolic reprogramming in cancer
    Xie, Hong
    Simon, M. Celeste
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (41) : 16825 - 16832
  • [48] The cancer metabolic reprogramming and immune response
    Longzheng Xia
    Linda Oyang
    Jinguan Lin
    Shiming Tan
    Yaqian Han
    Nayiyuan Wu
    Pin Yi
    Lu Tang
    Qing Pan
    Shan Rao
    Jiaxin Liang
    Yanyan Tang
    Min Su
    Xia Luo
    Yiqing Yang
    Yingrui Shi
    Hui Wang
    Yujuan Zhou
    Qianjin Liao
    Molecular Cancer, 20
  • [49] Editorial: Metabolic reprogramming in breast cancer
    Scatena, Cristian
    Naccarato, Antonio Giuseppe
    Ozsvari, Bela
    Scumaci, Domenica
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Metabolic reprogramming in cancer: Mechanisms and therapeutics
    Nong, Shiqi
    Han, Xiaoyue
    Xiang, Yu
    Qian, Yuran
    Wei, Yuhao
    Zhang, Tingyue
    Tian, Keyue
    Shen, Kai
    Yang, Jing
    Ma, Xuelei
    MEDCOMM, 2023, 4 (02):